Mylan said Wednesday that its subsidiary in India will be the primary supplier of antiretroviral (ARV) drugs to the South African National Department of Health for three years starting in April.
As part of the agreement, Mylan will be responsible for manufacturing and supplying triple-therapy, fixed-dose combination (FDC) treatments, which are used to treat HIV patients.
"Mylan's selection by the South African Department of Health as a leading supplier of ARVs reinforces our longstanding commitment to fighting HIV/AIDS in both South Africa and around the world. We are proud of our progress to date in stemming the tide of the disease, with approximately 40 percent of those being treated in the developing world today depending on our ARV products. But with more than 35 million people affected globally, there is more work to be done," Mylan CEO Heather Bresch said. "This deal supports our mission to provide the world's 7 billion people access to high-quality medicine, including affordable ARVs, and we look forward to working with the South African government on this important effort."
Mylan has produced these types of medications to over 100 countries. The company entered the South African market in 2012.
Want to get notified whenever we write about Mylan Inc. ?
Sign-up Next time we write about Mylan Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.